NasdaqGM:MNKD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States.


Snowflake Analysis

Limited growth with weak fundamentals.

Share Price & News

How has MannKind's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MNKD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.5%

MNKD

3.1%

US Biotechs

4.0%

US Market


1 Year Return

55.7%

MNKD

24.3%

US Biotechs

4.9%

US Market

Return vs Industry: MNKD exceeded the US Biotechs industry which returned 24.2% over the past year.

Return vs Market: MNKD exceeded the US Market which returned 5% over the past year.


Shareholder returns

MNKDIndustryMarket
7 Day3.5%3.1%4.0%
30 Day26.1%7.3%1.3%
90 Day90.4%31.2%29.5%
1 Year55.7%55.7%25.5%24.3%7.2%4.9%
3 Year53.0%53.0%32.8%28.4%36.1%27.2%
5 Year-93.3%-93.3%0.04%-5.7%65.3%46.9%

Price Volatility Vs. Market

How volatile is MannKind's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MannKind undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether MannKind is trading at an attractive price based on the cash flow it is expected to produce in the future. But as MannKind has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is MannKind forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

66.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MNKD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MNKD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MNKD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MNKD's revenue (26.1% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: MNKD's revenue (26.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MNKD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has MannKind performed over the past 5 years?

24.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MNKD is currently unprofitable.

Growing Profit Margin: MNKD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MNKD is unprofitable, but has reduced losses over the past 5 years at a rate of 24.8% per year.

Accelerating Growth: Unable to compare MNKD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MNKD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: MNKD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is MannKind's financial position?


Financial Position Analysis

Short Term Liabilities: MNKD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MNKD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MNKD has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MNKD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MNKD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MNKD has less than a year of cash runway if free cash flow continues to reduce at historical rates of 0.5% each year


Next Steps

Dividend

What is MannKind current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MNKD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MNKD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MNKD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MNKD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MNKD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Michael Castagna (43yo)

3.17yrs

Tenure

US$1,551,765

Compensation

Dr. Michael E. Castagna, Pharm.D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016  ...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD1.55M) is about average for companies of similar size in the US market ($USD2.15M).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Castagna
CEO & Director3.17yrsUS$1.55m0.098% $374.1k
Steven Binder
Chief Financial Officer3yrsUS$937.85k0.0027% $10.3k
David Thomson
Executive VP18.5yrsUS$988.41k0.13% $487.9k
James McCauley
Chief Commercial Officer3yrsUS$921.51k0.026% $98.7k
David Kendall
Chief Medical Officer2.42yrsUS$1.01m0.029% $110.3k
Joseph Kocinsky
Chief Technology Officer4.75yrsUS$707.89k0.010% $39.3k
Rosabel Alinaya
VP of Investor Relations & Treasuryno dataUS$519.59k0.017% $66.5k
Stuart Tross
Chief People & Workplace Officer3.58yrsUS$1.04m0.049% $187.4k
John Bedard
Senior Vice President of Worldwide Regulatory Affairs14.75yrsno datano data

3.4yrs

Average Tenure

56yo

Average Age

Experienced Management: MNKD's management team is considered experienced (3.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Castagna
CEO & Director3.17yrsUS$1.55m0.098% $374.1k
Ronald Consiglio
Independent Director16.75yrsUS$169.49k0.055% $211.0k
Kent Kresa
Independent Chairman4.42yrsUS$196.99k0.13% $510.5k
Jay Skyler
Member of Scientific Advisory Boardno datano datano data
Michael Friedman
Independent Director16.58yrsUS$162.69k0.034% $128.5k
Steven Edelman
Member of Scientific Advisory Boardno datano datano data
Julio Rosenstock
Member of Scientific Advisory Boardno datano datano data
Daniel Porte
Member of Scientific Advisory Boardno datano datano data
Geremia Bolli
Member of Scientific Advisory Boardno datano datano data
Brian Frier
Member of Scientific Advisory Boardno datano datano data

10.5yrs

Average Tenure

74.5yo

Average Age

Experienced Board: MNKD's board of directors are seasoned and experienced ( 10.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MNKD insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.5%.


Top Shareholders

Company Information

MannKind Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MannKind Corporation
  • Ticker: MNKD
  • Exchange: NasdaqGM
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$381.517m
  • Shares outstanding: 213.14m
  • Website: https://www.mannkindcorp.com

Number of Employees


Location

  • MannKind Corporation
  • 30930 Russell Ranch Road
  • Suite 300
  • Westlake Village
  • California
  • 91362
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MNKDNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJul 2004
NNFNDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2004

Biography

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/04 23:51
End of Day Share Price2020/07/02 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.